Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Interest & Investment Income (2017 - 2025)

Historic Interest & Investment Income for UroGen Pharma (URGN) over the last 8 years, with Q3 2025 value amounting to $979000.0.

  • UroGen Pharma's Interest & Investment Income fell 6233.17% to $979000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 426.27%. This contributed to the annual value of $8.7 million for FY2024, which is 14926.7% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Interest & Investment Income is $979000.0, which was down 6233.17% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Interest & Investment Income peaked at $2.8 million during Q4 2024, and registered a low of $2000.0 during Q1 2022.
  • Moreover, its 5-year median value for Interest & Investment Income was $768000.0 (2023), whereas its average is $981500.0.
  • In the last 5 years, UroGen Pharma's Interest & Investment Income tumbled by 9268.29% in 2021 and then soared by 3140000.0% in 2023.
  • Quarter analysis of 5 years shows UroGen Pharma's Interest & Investment Income stood at $20000.0 in 2021, then surged by 1930.0% to $406000.0 in 2022, then soared by 278.82% to $1.5 million in 2023, then skyrocketed by 78.8% to $2.8 million in 2024, then crashed by 64.4% to $979000.0 in 2025.
  • Its last three reported values are $979000.0 in Q3 2025, $1.3 million for Q2 2025, and $2.1 million during Q1 2025.